|Rapid Review Complete
|For the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full pharmacoeconomic assessment recommended at the submitted price.
The HSE has approved reimbursement following confidential price negotiation.